Sorry, you need to enable JavaScript to visit this website.
rana_h_200x300.jpg

Rana Al-Hallaq, PHD

Executive Director, WWBD / Partner

RANA AL-HALLAQ, PHD is Executive Director, WWBD and Partner at Pfizer Ventures. Rana is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in Arkuda Therapeutics, Autifony Therapeutics, Biograph55, Blade Therapeutics, Jnana Therapeutics, Mitokinin, Montis BioSciences, Nucleome Therapeutics, ReCode Therapeutics, RefleXion Medical, and Vivet Therapeutics. Her prior investment responsibilities include Cortexyme, Triplet Therapeutics, and VectivBio. She is also responsible for managing investments in the Dementia Discovery Fund and the Health Enterprise Partners Fund.

Prior to her current role, Rana was a Transactionalist in Worldwide Business Development at Pfizer where she was responsible for negotiating and transacting licenses, acquisitions, and partnerships across therapeutic areas. Rana joined Pfizer in 2015 as an Early Candidate Clinical Lead where she advised early clinical programs in CNS to ensure alignment with business strategies. Prior to joining Pfizer, she held roles at Allergan (formerly Actavis, formerly Forest Laboratories), first in Clinical Development Psychiatry as scientific and operational lead on Phase 2 and Phase 3 studies, and later in Business Development where she assessed and executed on a number of acquisitions and licenses across therapeutic areas. She began her training as a research fellow at the National Institutes of Health.

Rana received her BA in Biology from Hamilton College and holds a PhD in Neuroscience from Georgetown University Medical Center.

Email: [email protected]

Media Name: Barbara_v2_300x170.jpg
Barbara Dalton, PHD

Vice President, WWBD / Senior Managing Partner

Michael Baran headshot thumbnail
Michael Baran, MBA, PHD

Executive Director, WWBD / Partner

irena_melnickova_300x170.jpg
Irena Melnikova, PHD

Executive Director, WWBD / Partner

Media Name: Chris 300x170.png
Christopher O’Donnell, PHD

Vice President, WWBD / Partner

Denis headshot thumbnail
Denis Patrick, PHD

Vice President, WWBD / Managing Partner

marie-clarie_300x170.jpg
Marie-Claire Peakman, MRPHARMS, PHD

Executive Director, WWBD / Partner

rana_h_200x300.jpg

Rana Al-Hallaq, PHD

Executive Director, WWBD / Partner

RANA AL-HALLAQ, PHD is Executive Director, WWBD and Partner at Pfizer Ventures. Rana is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in Arkuda Therapeutics, Autifony Therapeutics, Biograph55, Blade Therapeutics, Jnana Therapeutics, Mitokinin, Montis BioSciences, Nucleome Therapeutics, ReCode Therapeutics, RefleXion Medical, and Vivet Therapeutics. Her prior investment responsibilities include Cortexyme, Triplet Therapeutics, and VectivBio. She is also responsible for managing investments in the Dementia Discovery Fund and the Health Enterprise Partners Fund.

Prior to her current role, Rana was a Transactionalist in Worldwide Business Development at Pfizer where she was responsible for negotiating and transacting licenses, acquisitions, and partnerships across therapeutic areas. Rana joined Pfizer in 2015 as an Early Candidate Clinical Lead where she advised early clinical programs in CNS to ensure alignment with business strategies. Prior to joining Pfizer, she held roles at Allergan (formerly Actavis, formerly Forest Laboratories), first in Clinical Development Psychiatry as scientific and operational lead on Phase 2 and Phase 3 studies, and later in Business Development where she assessed and executed on a number of acquisitions and licenses across therapeutic areas. She began her training as a research fellow at the National Institutes of Health.

Rana received her BA in Biology from Hamilton College and holds a PhD in Neuroscience from Georgetown University Medical Center.

Email: [email protected]

Media Name: Barbara_v2_300x170.jpg
Barbara Dalton, PHD

Vice President, WWBD / Senior Managing Partner

Michael Baran headshot thumbnail
Michael Baran, MBA, PHD

Executive Director, WWBD / Partner

irena_melnickova_300x170.jpg
Irena Melnikova, PHD

Executive Director, WWBD / Partner

Media Name: Chris 300x170.png
Christopher O’Donnell, PHD

Vice President, WWBD / Partner

Denis headshot thumbnail
Denis Patrick, PHD

Vice President, WWBD / Managing Partner

marie-clarie_300x170.jpg
Marie-Claire Peakman, MRPHARMS, PHD

Executive Director, WWBD / Partner